ADJUVANT BRAIN CANCER STUDIES

Temozolomide–Based Chemoradiotherapy Regimen for High-Risk Low Grade Glioma (R0424)

NEOADJUVANT BREAST CANCER STUDIES

Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane, Letrozole, or Anastrazole in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer (Z1031)

ADJUVANT BREAST CANCER STUDIES

Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Pre-Menopausal Women with Endocrine Responsive Breast Cancer (IBCSG 24-02)

A Randomized Phase III Study of Conventional Whole Breast Irradiation vs. Partial Breast Irradiation for Women with Stage 0, I, II Breast Cancer (NSABP B-39)

Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment – the TAILOR-X Trial (PACCT-1)

A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Node Negative Breast Cancer (E5103)

ADJUVANT GASTROINTESTIONAL CANCER STUDIES

Randomized Phase II Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (E5202) – Accrual presently suspended

A Randomized Phase III Trial of Oxaliplatin plus 5-FU & Leucovorin with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer (N0147)  

ADVANCED GASTROINTESTINAL CANCER STUDIES

Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab or Cetuximab (C225) or with the Combination of Bevacizumab & Cetuximab for patients with untreated Metastatic adenocarcinoma or colon or rectum (C80405)

A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination with Gemcitabine in Subjects with Metastatic Pancreatic Cancer (Agensis 2008002)

ADVANCED GENITOURINARY CANCER STUDIES

Double Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Unfavorable Resected Renal Cell Cancer: ASSURE (E2805)

A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer (R0521)

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy (R0534 SSPORT)

A Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma (VEG108844)

ADJUVANT LUNG CANCER STUDIES

A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-positive Non-Small Cell Lung Cancer (MAGE-A3 MAGRIT)

ADVANCED LUNG CANCER STUDIES

A Randomized Phase II, Multi-Center, Open-Label Trial of PR104 and Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer (PR104-2003 Proacta)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated with Systemic Chemotherapy (Merck 014-04)

ADJUVANT MELANOMA STUDIES

Phase III Randomized Study of Four Weeks High Dose Interferon Alfa 2b in Stage II B Melanoma (E1697)

MULTIPLE MYELOMA STUDIES

Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma who are not considered Candidates for High-dose Chemotherapy and Autologous Stem Cell Transplantation: Velcade, Thalidomide, and Dexamethasone (VTD) versus Velcade and Dexamethasone (VD) versus Velcade, Melphalan and Prednisone (VMP) (C05009 UPFRONT)

LYMPHOMA STUDIES

A Phase 3 Multicenter, Open-Label Study of Rituximab Faster Infusion Time in Patients With Previously Untreated Diffuse Large B-Cell Or Follicular Non-Hodgkin’s Lymphoma (U4391g RATE)

MISCELLANEOUS
(METASTATIC OR LOCALLY ADVANCED LUNG, PANCREAS, STOMACH, COLON/RECTUM, BLADDER/OVARY)

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy (EFC6521 SAVE-ONCO)